WO1998011105A1 - Nouveaux composes pharmaceutiquement actifs - Google Patents
Nouveaux composes pharmaceutiquement actifs Download PDFInfo
- Publication number
- WO1998011105A1 WO1998011105A1 PCT/SE1997/001505 SE9701505W WO9811105A1 WO 1998011105 A1 WO1998011105 A1 WO 1998011105A1 SE 9701505 W SE9701505 W SE 9701505W WO 9811105 A1 WO9811105 A1 WO 9811105A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- indolyl
- formula
- amino
- compound
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 136
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 45
- 239000001257 hydrogen Substances 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 6
- -1 (C^CgJalkoxymethyl Chemical group 0.000 claims description 31
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 18
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 16
- 150000002431 hydrogen Chemical group 0.000 claims description 16
- 125000003277 amino group Chemical group 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 13
- UGUUDTWORXNLAK-UHFFFAOYSA-N azidoalcohol Chemical group ON=[N+]=[N-] UGUUDTWORXNLAK-UHFFFAOYSA-N 0.000 claims description 12
- 150000001540 azides Chemical group 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 9
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 239000012351 deprotecting agent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000004849 alkoxymethyl group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
- OKKJLVBELUTLKV-MZCSYVLQSA-N CD3OD Substances [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 47
- 239000000203 mixture Substances 0.000 description 41
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000000047 product Substances 0.000 description 32
- 239000000243 solution Substances 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 8
- 102000003923 Protein Kinase C Human genes 0.000 description 8
- 108090000315 Protein Kinase C Proteins 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000001828 Gelatine Substances 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- ANBITDTVMQXCKV-UHFFFAOYSA-N 3-(1h-indol-2-yl)-4-(1-methylindol-3-yl)furan-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C1=C(C=2NC3=CC=CC=C3C=2)C(=O)OC1=O ANBITDTVMQXCKV-UHFFFAOYSA-N 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000003924 bisindolylmaleimides Chemical class 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- HSFWSUASNBDOBE-UHFFFAOYSA-N 3,4-bis(1h-indol-2-yl)furan-2,5-dione Chemical compound C1=CC=C2NC(C=3C(=O)OC(C=3C=3NC4=CC=CC=C4C=3)=O)=CC2=C1 HSFWSUASNBDOBE-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000020176 deacylation Effects 0.000 description 3
- 238000005947 deacylation reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000003949 imides Chemical class 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- PDVFSPNIEOYOQL-UHFFFAOYSA-N (4-methylphenyl)sulfonyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OS(=O)(=O)C1=CC=C(C)C=C1 PDVFSPNIEOYOQL-UHFFFAOYSA-N 0.000 description 2
- 208000012657 Atopic disease Diseases 0.000 description 2
- 0 CC1OC(*)*(C)(C)C(*)C1* Chemical compound CC1OC(*)*(C)(C)C(*)C1* 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000014997 Crohn colitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical class C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 description 2
- 229960005544 indolocarbazole Drugs 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 238000011894 semi-preparative HPLC Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- DGQOCLATAPFASR-UHFFFAOYSA-N tetrahydroxy-1,4-benzoquinone Chemical compound OC1=C(O)C(=O)C(O)=C(O)C1=O DGQOCLATAPFASR-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- KXNRAPQYUAQAFX-LYFYHCNISA-N (2s,4s,6r)-2-(hydroxymethyl)-6-methoxyoxan-4-ol Chemical compound CO[C@H]1C[C@@H](O)C[C@@H](CO)O1 KXNRAPQYUAQAFX-LYFYHCNISA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- VQEDENJDYAWVOH-UHFFFAOYSA-N 2-methoxy-2-methylpropane;toluene Chemical compound COC(C)(C)C.CC1=CC=CC=C1 VQEDENJDYAWVOH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 244000165918 Eucalyptus papuana Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000575946 Ione Species 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- CELPHAGZKFMOMR-UHFFFAOYSA-N azanium;dichloromethane;methanol;hydroxide Chemical compound [NH4+].[OH-].OC.ClCCl CELPHAGZKFMOMR-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000003925 isoquinoline sulfonamides Chemical class 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000011981 lindlar catalyst Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- XYKIUTSFQGXHOW-UHFFFAOYSA-N propan-2-one;toluene Chemical compound CC(C)=O.CC1=CC=CC=C1 XYKIUTSFQGXHOW-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
Definitions
- the present invention relates to novel bisindolylmaleimides, methods for their preparation, intermediates therefor and pharmaceutical compositions comprising them.
- PLC Protein kinase C
- PKC inhibitors e.g. isoquinoline sulphonamides, sphingosine and related sphingolipids and indolocarbazoles.
- EP, Bl, 0328026 discloses the use of bisindolylmaleimides, a class of compounds related to the indolocarbazoles, in medicaments for the treatment of various diseases.
- novel bisindolylmaleimides which are PKC inhibitors.
- the compounds of formula (I) and pharmaceutically acceptable salts thereof are active topically, moreover, they have a systemic activity when administered orally, and certain of them have enhanced anti-inflammatory effect.
- Compounds of the present invention possess improved ability to inhibit PKC relative to compounds of the closest structural prior art and /or possess improved solubility and /or improved bioavailability and /or improved oral activity.
- the object of the present invention is to provide these novel bisindolylmaleimides, methods for their preparation and intermediates used for their preparation.
- Another object of the present invention is the use of the novel compounds for the treatment of inflammatory and immunological disorders and preferably for oral or topical treatment of inflammatory and immunological disorders, such as the oral or topical treatment of airway diseases involving inflammatory conditions, e.g. asthma; bronchitis and atopic diseases, e.g. rhinitis and atopic dermatitis; psoriasis; inflammatory bowel diseases, e.g. Crohn's disease and colitis; rheumatoid arthritis and malignant diseases (e.g. skin and lung cancer).
- airway diseases involving inflammatory conditions
- bronchitis and atopic diseases e.g. rhinitis and atopic dermatitis
- psoriasis e.g. rhinitis and atopic dermatitis
- psoriasis e.g. Crohn's disease and colitis
- rheumatoid arthritis and malignant diseases e.g
- Still another object of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising a compound according to the invention, as active ingredient, together with a pharmaceutically acceptable adjuvant, diluent or carrier.
- X is hydrogen or methyl
- R is a group of formula (II)
- n 0 or 1
- R 2 is hydrogen
- R 4 is hydrogen, hydroxy, azide, amino, N-((C 1 -C 5 )alkyl)amino or N,N-di((C 1 - C 5 )alkyl)amino,
- R 2 and R 4 may together form a bond
- R 6 may be hydrogen, hydroxy, azide, amino or N,N-di((C 1 -C 5 )alkyl)amino, and
- R 7 is hydrogen, hydroxy methyl, (C 1 -C 5 )alkoxy methyl, azidomethyl,
- R 7 is hydroxymethyl, by deprotecting a corresponding compound of formula (I) in which one or both of R 4 and R 6 is a protected hydroxyl group, and /or R 7 is a methylene carrying a protected hydroxyl group, or
- R 4 and R 6 is a protected hydroxyl group or a protected amino group
- R 7 is a methylene carrying a protected hydroxyl group or a methylene carrying a protected amino group
- the protecting group may be an acyl group such as acetyl or benzoyl
- the deprotecting agent may be a base such as sodium methoxide.
- the deprotection step may be carried out in a suitable solvent, e.g. methanol at a temperature between 20°C to reflux for, for example, 1 hour to 24 hours.
- the conditions for the reduction are well known to those skilled in the art.
- Preferred conditions are: i) hydrogenation over Pd/C or Lindlar catalyst, e.g. at atmospheric pressure and at a temperature of 10-30°C and using a protic solvent, e.g. ethanol or a mixture of ethanol and ethyl acetate;
- sulphide in a suitable solvent, e.g. hydrogen sulphide (gas) in a mixture of pyridine and water;
- triphenyl phosphine in a suitable solvent, e.g. tetrahydrofuran at a temperature of 10-30°C, e.g. for about 30 h followed by either acidic extraction or chromatographic purification.
- a suitable solvent e.g. tetrahydrofuran at a temperature of 10-30°C, e.g. for about 30 h followed by either acidic extraction or chromatographic purification.
- the protecting groups and conditions for deprotection are well known to those skilled in the art.
- the protecting group may be a phthaloyl group and the deprotecting agent may be methylamine in ethanol.
- the deprotecting step may be carried out in a suitable solvent, e.g. tetrahydrofuran at about 10-30°C for about 22 hours.
- the good leaving group may be obtained by transformation of a corresponding hydroxy or hydroxymethyl to a better leaving group, e.g. p-toluenesulphonyloxy group.
- An appropriate amine may be ammonia, monoalkylamine or dialkylamine. Suitable leaving groups are well known to those skilled in the art.
- the intermediate compound possessing a good leaving group may be isolated or generated in situ.
- the appropriate source of ammonia may be hexamethyldisilazane, and the reaction may be performed with hexamethyldisilazane and methanol in a polar solvent, e.g. dimethylformamide at a temperature of 10-30°C.
- the protecting groups may be acyl or phthaloyl groups, the removal of the protecting groups may be carried out according to conventional methods known per se (e.g. deacylation, catalytic hydrogenation and dephthaloylation), and prefererred conditions for the deprotection step are as defined above under a) and c) above.
- the conversion may be carried out by conventional processes known per se, e.g. reaction of the free base with an acid containing the desired anion, or by careful basification of the salt.
- the reaction may be carried out in a suitable solvent, e.g. ethanol or methylene chloride.
- the starting materials for the above processes may be made by the methods set out in the Examples or by methods analogous thereto. Other conventional methods for making the starting materials will be evident to those skilled in the art.
- the compounds of formula (III) may be prepared by reacting a compound of formula (IV)
- Hal is a halogen atom, preferably chlorine, and R ⁇ is R or X, both as defined in formula (III), with
- R is R or X, both as defined in formula (IE), in the presence of an appropriate organic base, e.g. triethylamine.
- a compound of the formula (IV) may be prepared by reacting a compound of formula (VI)
- R ⁇ is as defined in formula (IV), with
- a compound of formula (VI) in which R ⁇ is R, may be prepared by reacting a compound of the general formula (VII)
- oxidant e.g. 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (DDQ) in a suitable solvent, e.g. toluene.
- DDQ 2,3-dichloro-5,6-dicyano-l,4-benzoquinone
- a compound of formula (VH) may be prepared by reacting a compound of formula (VIII),
- R and X are as defined in formula (El), and Z is NCH ⁇ OCH j H j ,
- VELA a compound of formula (VELA), which is as defined in formula (VIII), but wherein Y is hydroxyl, acetoxy or methoxy, with
- a Lewis acid e.g. boron trifluoride etherate or t-butyldimethylsilalyl trifluoromethanesulphonate in a solvent, e.g. acetonitrile, dichloromethane or a mixture of the two solvents at a temperature between -60°C and ambient temperature.
- a Lewis acid e.g. boron trifluoride etherate or t-butyldimethylsilalyl trifluoromethanesulphonate
- a solvent e.g. acetonitrile, dichloromethane or a mixture of the two solvents at a temperature between -60°C and ambient temperature.
- Compounds of formula (EIA) may be converted to a compound of formula (III) by treatment with a strong base, e.g. aqueous sodium hydroxide followed by acidification, e.g. with aqueous hydrogen chloride.
- Hal is an halogen atom, preferably chlorine, and R is as defined in formula (III).
- R is as defined in formula (III).
- Y a is methoxy, R 4a is benzoyloxy, R 6a is hydrogen and R 9a is 4-methylphenylsulphonoxy, azide or N-phthalimide; or
- Y a is hydroxy, R 4a is azide, R 6a is hydrogen and R 9a is benzoyloxy.
- the preferred protecting groups for i), ii), iii) and iv) immediately above, are as defined above under processes a) and c) above.
- v) may be a compound of formula (VIEA) wherein Y a is methoxy, R 4a is azide, R 6a is hydrogen or benzoyloxy and R 9a is benzoyloxy; or
- Y a is methoxy
- R 4a is benzoyloxy
- R 6a is benzoyloxy
- R 9a is azide
- Y a may also be an acyloxy group.
- the compounds of formula (I), and pharmaceutically acceptable salts thereof, are useful because they demonstrate pharmacological activity.
- they demonstrate activity as PKC inhibitors, e.g. as is shown by their activity in the i vitro assays described in Granet, R. A. et al, Analyt. Biochem. 1987; 163.458-463;
- the compounds are generally active in the above test with IC M -values ranging from 1-1000 nM.
- the compounds of the invention are active topically, moreover, they have a systemic activity when administred orally, and certain of them have enhanced anti-inflammatory effect.
- the compounds of the invention are indicated for use in the treatment of inflammatory and immunological disorders, e.g. topical or systemic treatment of airway diseases involving inflammatory conditions, e.g. asthma; bronchitis and atopic diseases, e.g. rhinitis and atopic dermatitis; psoriasis; inflammatory bowel diseases, e.g. Crohn's disease and colitis; rheumatoid arthritis and malignant diseases (e.g. skin and lung cancer).
- the compounds may be administered at a dosage from about 10 ⁇ g to 10 mg per day either as a single dose or in divided doses 2 to 4 times per day.
- unit doses comprise from 2.5 ⁇ g to 10 mg of a compound according to the invention.
- the compounds may be administered topically, e.g. to the lung and/or the airways, in the form of solutions, suspensions, HFA areosols and dry powder formulations, e.g. Turbuhaler formulations; or systemically, e.g. by oral administration in the form of tablets, pills, capsules, syrups, powders or granules, or by parenteral administration in the form of sterile parenteral solutions or suspensions, or by rectal administration in the form of suppositories.
- the compounds of the invention may be administered on their own or as a pharmaceutical composition comprising the compound of the invention in combination with a pharmaceutically acceptable diluent, adjuvant or carrier.
- a pharmaceutically acceptable diluent, adjuvant or carrier particularly preferred are compositions not containing material capable of causing an adverse, e.g. an allergic, reaction.
- Dry powder formulations and pressurized HFA aerosols of the compounds of the invention may be administred by oral or nasal inhalation.
- the compound is desireably finely divided.
- the finely divided compound preferably has a mass median diameter of less than 10 ⁇ m, and may be suspended in a propellant mixture with the assistance of a dispersant, such as a C S -C 2Q fatty acid or salt thereof, (e.g. oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.
- a dispersant such as a C S -C 2Q fatty acid or salt thereof, (e.g. oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.
- the compounds of the invention may also be administered by means of a dry powder inhaler.
- the inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler.
- a carrier substance e.g. a mono-, di- or polysaccharide, a sugar alcohol or another polyols.
- Suitable carriers are sugars, e.g. lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch.
- the finely divided compound may be coated by another substance.
- the powder mixture may also be dispensed into hard gelatine capsules, each containing the desired dose of the active compound.
- This spheronized powder may be filled into the drug reservoir of a multidose inhaler, e.g. that known as the Turbuhaler in which a dosing unit meters the desired dose which is then inhaled by the patient.
- a multidose inhaler e.g. that known as the Turbuhaler in which a dosing unit meters the desired dose which is then inhaled by the patient.
- the active compound with or without a carrier substance is delivered to the patient.
- the pharmaceutical composition comprising the compound of the invention may conveniently be tablets, pills, capsules, syrups, powders or granules for oral administration; sterile parenteral solutions or suspensions for parenteral administration or suppositories for rectal administration.
- the active compound may be admixed with an adjuvant or a carrier, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatine or polyvinylpyrrolidone, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets.
- a carrier e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatine or polyvinylpyrrolidone, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets.
- the compound may be admixed with e.g. a vegetable oil or polyethylene glycol.
- Hard gelatine capsules may contain granules of the compound using either the above mentioned excipients for tablets, e.g. lactose, saccharose, sorbitol , mannitol, starches, cellulose derivatives or gelatine. Also liquid or semisolid formulations of the drug may be filled into hard gelatine capsules.
- Liquid preparations for oral application may be in the form of syrups or suspensions, for example solutions containing the compound, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol.
- Such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.
- the compounds of the invention may also be administered in conjunction with other compounds used for the treatment of the above conditions.
- Preferred compounds of the formula (I) are those, wherein
- R 4 is hydrogen, hydroxy, azide, amino or N,N-di((C 1 -C 3 )alkyl)amino,
- R 2 and R 4 may together form a bond
- R 6 may be hydrogen, hydroxy, azide, amino or N,N-di((C C 3 )alkyl)amino, and
- R 7 is hydrogen, hydroxymethyl, (C 1 -C 3 )alkoxymethyl, azidomethyl, aminomethyl, N,N- di((C 1 -C 3 )alkyl)aminomethyl.
- Particularly preferred compounds of the formula (I) are those, wherein
- R 4 is hydroxy, azide, amino or N,N-diethylamino, when n is 1 R 6 may be hydrogen, hydroxy, azide, amino or N,N-diethylamino, and
- R 7 is hydroxymethyl, methoxymethyl, azidomethyl, aminomethyl, (N,N- diethylamino)methyl.
- the most preferred compounds according to the present invention include:
- the most preferred compound according to the present invention is :
- Enantiomers and diastereomers of compounds of the formula (I) may be prepared by stereospecific synthesis or by resolution of mixtures containing them. The resolution ma be carried out using processes known per se.
- the bisindolylmaleic anhydride (acceptor) is dissolved in a minimal amount of hot acetonitrile and diluted with an equal volume of toluene.
- the solvents are distilled off under reduced pressure and the residue is dried overnight at 0.05 torr at room temperature.
- the bisindolylmaleic anhydride (acceptor) is dissolved in the reaction solvent to obtain 20-100 M solution.
- the reaction solvent is acetonitrile (dried over 3 A molcular sieves) or a mixture of acetonitrile (dried over 3 A molcular sieves) and dichloromethane (dried over 4A molcular sieves) (1:6 - 3:2).
- acetonitrile dried over 3 A molcular sieves
- dichloromethane dried over 4A molcular sieves
- ground 4A molecular sieves are added (0.1- 0 .5g/ml).
- the solution is cooled to the indicated temperature (-20 to -60°C) and 1 to 10 equivalents (preferrably 1.5 to 4 equivalents) of the promoter is added.
- Promoters used are boron trifluoride etherate, trimethylsilyl trifluoromethanesulfonate and dimethyl- t-buty lsily 1 trifluoromethanesulfonate .
- reaction is monitored by TLC and /or HPLC and terminated by addition of a base such as triethylamine or aqueous sodium hydrogen carbonate and allowed to attain ambient tempreature. If ground molecular sieves were included, the
- TM mixture is filtered through a celite pad.
- the filtrate is washed with aqueous sodium hydrogen carbonate, water and the organic phases are then dried over sodium sulfate, filtered and the solvents removed under reduced pressure and the residue subjected to either straight or reverse phase column chromatography unless otherwise indicated.
- a 0.1-0.25 mM solution of the glycosylated bisindolylmaleic anhydride in dimethylformamide is treated with 5 to 30 equivalents (preferrably 8 to 12 equivalent) of hexamethyldisilazane and 2.5 to 15 equivalents (preferrably 4 to 6 equivalents) of methanol at ambient temperature.
- the reaction is complete as indicated by TLC, the solvents and reagents are removed under reduced pressure and the residue crystallized or subjected to column chromatography
- a 50-250 mM tetrahydrofuran solution of the azide is treated with 5 to 10 equivalents of triphenylphosphine and 10 to 20 equivalents of water in a flask, protected from light, overnight or until the reaction is complete as indicated by TLC.
- the reaction mixture is then either concentrated under reduced pressure and the residude subjected to chromatography (to afford the free amine) or partitioned between 5% aquous acetic acid and chloroform or ethyl acetate, the aquous phase is washed with another portion of the organic solvent and concentrated under reduced pressure or lyophilized to obtain the acetic acid salt.
- the aquous solution is made weakly alkaline with sodium hydrogen carbonate and the amine extracted with an organic solvent which is then dried over sodium sulfate and the solvent is removed under reduced pressure.
- the product is then purified either by crystallization or column chromatography.
- RP-8 and RP-18 acetonitrile / water ( 2:1 to 9:1) with most intermediate products, acetonitrile / water ( 1:4 to 2:1, 1% acetic acid or 0.1% trifluoroacetic acid) with basic products.
- 3-Indolyl-4-(l-methyl-3-indolyl)-furan-2,5-dione was dissolved in a mixture of acetonitrile and dichloromethane (18:8, 26 mL) and cooled to -45°.
- Tert- Butyldimethylsilyl trifluoromethanesulfonate (540 ⁇ L, 2.34 mmol) was added, followed by addition of the product from step a) (308 mg, 0.78 mmol) dissolved in a mixture of acetonitrile and dichloromethane (2:5, 7 mL).
- step d) The product from step d) (87 mg, 185 ⁇ mol) was dissolved in 0.03 M acetic acid in water (30 mL) and lyophilised to afford the amorphous title compound (95 mg, 97 %).
- step d) 3-fl-( ' 6-Azido-3-0-benzoyl-2,4,6-trideoxy- ⁇ -D-threo-hexopyranosyl)-indol-3-yl ⁇ -4-(l- methyl-3-indolyl)- pyrrolo-2.5-dione
- the product from step d) (52.0 mg, 86.5 ⁇ mol) was subjected to the general method for imide formation.
- the reaction mixture was concentrated under reduced pressure and the residue was subjected to flash chromatography ( toluene- t-butyl methyl ether, 8:1) to afford the sub-title compound (33.5 mg, 65%).
- step f) The product from step e) (33.0 mg, 54.9 ⁇ mol) was deacylated according to the general deacylation procedure, the reaction mixture was neutralised with silica (ca lg), filtered and concentrated under reduced pressure and the residue was subjected to the general procedure for azide reduction. The mixture was directly applied on a 70 g Lobar C-18 column and the red material which eluted with acetonitrile-water 1:4, 0.1% trifluoroacetic acid was collected and concentrated under reduced pressure.
- Example 3 3-[l-(3-Azido-2,3-dideoxy- ⁇ -D-threo-pentofuranosyl)-3-indolyl]-4-(l-methyl-3- indolyl)-pyrroIe-2,5-dione,
- p-Toluenesulfonic anhydride (6.9 g, 20.6 mmol) was added to a solution of methyl-2- deoxy-5-O- (4-phenylbenzoyl) - ⁇ -D-erythro-pentofuranoside (4.5 g, 13.7 mmol) in pyridine (3.3 mL, 41.2 mmol) and dry dichloromethane (100 mL) at 0° C. The mixture was stirred at 0° C for 1.5 hour, poured on ice-cold saturated aqueous sodium hydrogen carbonate (200 mL), extracted with dichloromethane (2x250 mL), dried and concentrated under reduced pressure. The residue was filtered through a short silica gel column (heptane-ethyl acetate, 1:1) to give the crude sub-title compound (6.3 g, 89%, approx. 90 % pure).
- step e 3-ri- ( 3-Azido-2.3-dideoxy- ⁇ -D-threo-pentofuranosyl)-3-indolyll-4-(l-methyl-3- indoly l)-pyrrole-2 ,5-dione
- the product from step e) (2.3 g, 3.47 mmol) was dissolved in dichloromethane- methanolic 0.01 M sodium methoxide (3:1, 160 mL) and stirred at room temperature overnight.
- the solution was neutralised with cation exchange resin (Bio-Rad, AG 50W- X8, H * ), filtered and concentrated under reduced pressure.
- step f) The product from step f) (980 mg, 1.48 mmol) was dissolved in dichloromethane- methanolic 0.03 M sodium methoxide (3:4, 70 mL) and the mixture was stirred at room temperature for 3 h., neutralised with silica gel, filtered and concentrated under reduced pressure. The residue was subjected to chromatography (heptane-ethyl acetate, 3:1) to afford the sub-title compound (695 mg, 97%).
- step j) The product from step j) (92 mg, 43.8 ⁇ mol) was dissolved in aqueous 0.02 M acetic acid (25 mL) and lyophilised to give the title product 3 B) (98 mg, 94%). l H-N.m.r.
- step i) The product from step i) (100 mg, 219 ⁇ mol) was dissolved in aqueous 0.03 M acetic acid (30 mL) and lyophilised to afford the title compound 3 C) (108 mg, 96%).
- Example 4 The compounds in Example 4 were prepared in analogy with the compounds described in Examples 1, 2 and 3 above.
- Methyl 3-0-benzoyl-6-phthalimido-2,4,6-trideoxy- ⁇ -D-threo-hexopyranoside (2.2 g, 5.6 mmol) dissolved in acetonitrile (80 mL) and aqueous hydrogen chloride (0.5 M, 80 mL) was stirred at 100° C for 35 min. The mixture was extracted with ethyl acetate (500 mL). The organic phase was washed with saturated aqueous sodium hydrogencarbonate(200 mL), dried and concentraded under reduced pressure to give the sub-title compound (2.1 g, 90%).
- step a) The product from step a) (2.7 g, 7.0 mmol) and indoline (1.58 mL, 14.0 mmol) was stirred in toluene-ethanol (60 mL, 5:1) for 2 h at room temperature. The mixture was concentrated under reduced pressure to give the crude sub-title compound, which was used immediately.
- step b) The product from step b) (7.0 mmol) and 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (3.2 g, 14.0 mmol) was stirred at room temperature for 1 h, filtered through celiteTM and concentrated under reduced pressure. Column chromatography (toluene-ethyl acetate, 40:1) and crystallisation from ethyl acetate-ethanol (10:1) gave the sub-title compound, (2.1 g, 65%).
- step c) 3-ri- ( 3-0-Benzoyl-6-phthalimido-2,4.6-trideoxy- ⁇ -D-threo-hexopyranosyD-3- indolyn-4-d-methyl-3-indolyl)-furan-2,5-dione
- oxalyl chloride 183 ⁇ L, 2.1 mmol
- step d) The crude product from step d) (0.21 mmol) was subjected to the general method for imide formation and the mixture was concentrated under reduced pressure. Column chromatography (toluene-ethyl acetate, 4:1) gave title product (24 mg, 16%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU41432/97A AU4143297A (en) | 1996-09-10 | 1997-09-08 | New pharmaceutically active compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9603284A SE9603284D0 (sv) | 1996-09-10 | 1996-09-10 | New compounds |
SE9603284-2 | 1996-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998011105A1 true WO1998011105A1 (fr) | 1998-03-19 |
Family
ID=20403829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1997/001505 WO1998011105A1 (fr) | 1996-09-10 | 1997-09-08 | Nouveaux composes pharmaceutiquement actifs |
Country Status (5)
Country | Link |
---|---|
AR (1) | AR009733A1 (fr) |
AU (1) | AU4143297A (fr) |
SE (1) | SE9603284D0 (fr) |
WO (1) | WO1998011105A1 (fr) |
ZA (1) | ZA977808B (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097108A1 (fr) * | 2004-04-08 | 2005-10-20 | Novartis Ag | Inhibiteurs de proteine kinase c destines au traitement de maladies auto-immunes et de rejets de transplantation |
WO2005042002A3 (fr) * | 2003-10-30 | 2008-01-10 | Entelos Inc | Traitement de la polyarthrite rhumatoide a l'aide d'antagonistes de la proteine flip |
RU2413511C2 (ru) * | 2004-04-08 | 2011-03-10 | Новартис Аг | Ингибиторы протеинкиназы с, предназначенные для лечения аутоиммунных заболеваний и отторжения трансплантата |
CN108264503A (zh) * | 2018-02-13 | 2018-07-10 | 东华大学 | 一种3-吲哚马来酰亚胺化合物的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0328026A1 (fr) * | 1988-02-10 | 1989-08-16 | F. Hoffmann-La Roche Ag | Pyrroles substitués |
WO1991013071A1 (fr) * | 1990-02-26 | 1991-09-05 | Boehringer Mannheim Gmbh | Nouveaux pyrroles trisubstitues, leur procede de fabrication, et medicaments renfermant ces composes |
WO1995017182A1 (fr) * | 1993-12-23 | 1995-06-29 | Eli Lilly And Company | Inhibiteurs de la proteine-kinase c |
-
1996
- 1996-09-10 SE SE9603284A patent/SE9603284D0/xx unknown
-
1997
- 1997-08-29 ZA ZA9707808A patent/ZA977808B/xx unknown
- 1997-09-08 WO PCT/SE1997/001505 patent/WO1998011105A1/fr active Application Filing
- 1997-09-08 AU AU41432/97A patent/AU4143297A/en not_active Abandoned
- 1997-09-10 AR ARP970104133A patent/AR009733A1/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0328026A1 (fr) * | 1988-02-10 | 1989-08-16 | F. Hoffmann-La Roche Ag | Pyrroles substitués |
WO1991013071A1 (fr) * | 1990-02-26 | 1991-09-05 | Boehringer Mannheim Gmbh | Nouveaux pyrroles trisubstitues, leur procede de fabrication, et medicaments renfermant ces composes |
WO1995017182A1 (fr) * | 1993-12-23 | 1995-06-29 | Eli Lilly And Company | Inhibiteurs de la proteine-kinase c |
Non-Patent Citations (2)
Title |
---|
C. R. ACAD. SC., PARIS, Volume 283, Sept. 1976, M. TAM HUYNH DINH et al., "CHIMIE ORGANIQUE. - Glycosylation Directe du Noyau Indolique par un Desoxy-2 Ribose", pages 227-228. * |
JOURNAL OF HETEROCYCLIC CHEMISTRY, Volume 25, 1988, NABIH S. GIRGIS et al., "Synthesis of 2'-Deoxyribofuranosyl Indole Nucleosides Related to the Antibiotics SF-2140 and Neosidomycin", pages 361-366. * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005042002A3 (fr) * | 2003-10-30 | 2008-01-10 | Entelos Inc | Traitement de la polyarthrite rhumatoide a l'aide d'antagonistes de la proteine flip |
WO2005097108A1 (fr) * | 2004-04-08 | 2005-10-20 | Novartis Ag | Inhibiteurs de proteine kinase c destines au traitement de maladies auto-immunes et de rejets de transplantation |
AU2005230399B2 (en) * | 2004-04-08 | 2009-07-09 | Novartis Ag | Protein kinase C inhibitors for the treatment of autoimmune diseases and of transplant rejection |
RU2413511C2 (ru) * | 2004-04-08 | 2011-03-10 | Новартис Аг | Ингибиторы протеинкиназы с, предназначенные для лечения аутоиммунных заболеваний и отторжения трансплантата |
CN108264503A (zh) * | 2018-02-13 | 2018-07-10 | 东华大学 | 一种3-吲哚马来酰亚胺化合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
ZA977808B (en) | 1998-03-10 |
SE9603284D0 (sv) | 1996-09-10 |
AU4143297A (en) | 1998-04-02 |
AR009733A1 (es) | 2000-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3262057B1 (fr) | Dérivés de nucléosides substitués utiles en tant qu'agents anticancéreux | |
AU716279B2 (en) | New pharmaceutically active compounds | |
US7214685B2 (en) | Prodrugs for a selective cancer therapy | |
AU718844B2 (en) | New pharmaceutically active compounds | |
JP2000516250A (ja) | インドロピロロカルバゾールの細胞毒性アミノ糖および関連する糖誘導体 | |
KR20010031875A (ko) | 화학 화합물 | |
JPWO2003080635A1 (ja) | グルコピラノシルオキシベンジルベンゼン誘導体の結晶 | |
CN101754964A (zh) | Dna pk抑制剂 | |
JP2873086B2 (ja) | 複素環化合物 | |
KR100193593B1 (ko) | 6,9-비스 (치환된 아미노) 벤조 [g]이소퀴놀린 -5,10- 디논 및 이를 포함하는 약제학적 조성물 | |
WO1998011105A1 (fr) | Nouveaux composes pharmaceutiquement actifs | |
JPH05501404A (ja) | ヌクレオシド誘導体 | |
JPH0577676B2 (fr) | ||
KR910008799B1 (ko) | 에피포도필로톡신 배당체의 4'-아실 유도체 | |
JPH0269496A (ja) | イミダゾ〔4,5―b〕ピリジン誘導体 | |
WO1998011103A1 (fr) | Nouveaux composes pharmaceutiquement actifs | |
KR100624050B1 (ko) | 아라비노실아데닌 유도체 | |
EP3735233A1 (fr) | Composés glycoconjugués à base d'acide artémisinique, leur procédé de préparation et d'utilisation | |
US20150105543A1 (en) | Synthesis | |
KR102350002B1 (ko) | 탁산 화합물, 이들의 제조 방법, 및 이들의 용도 | |
JP3536574B2 (ja) | 抗腫瘍性インドロピロロカルバゾール誘導体 | |
US6610727B2 (en) | Anhydro sugar derivatives of indolocarbazoles | |
US6458792B1 (en) | Compounds | |
US5126347A (en) | Isomeric dideoxynuclesides | |
JPH09249690A (ja) | 4’−チオアラビノプリンヌクレオシド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 08973652 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998513560 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |